The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...

EMA committee recommends approval of AstraZeneca’s Imfinzi in combo with chemotherapy to treat resectable non-small cell lung cancer ...

In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments in terms of progression-free survival, according to AstraZeneca.

The pharmaceutical industry is evolving continuously with the advancements in drug discovery with Artificial Intelligence (AI ...

AstraZeneca secured approvals for two new molecular entities. Kavigale received EU approval for the prevention of COVID-19 in immunocompromised people aged 12 years and older. Datroway was ...

In January this year, AstraZeneca and partner Daiichi’s drug, Datroway/datopotamab deruxtecan was approved by the FDA for HR+ HER2- breast cancer while a regulatory application is under review ...

AstraZeneca, a global pharmaceutical company ... WILMINGTON, Del., January 17, 2025--DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients ...

So if actually AstraZeneca was found liable ... this year for several of our existing medicines including in HER2, Datroway, Imfinzi, Breztri and Fasenra. And importantly, we also anticipate ...

Wide-moat AstraZeneca’s fourth-quarter results were in line with our expectations. The company’s revenue guidance for 2025 was high-single-digit growth at constant currency, which we think is ...